Session: 702. CAR-T Cell Therapies: Basic and Translational: Poster III
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Translational Research, Diseases, Immunology, Lymphoid Malignancies, Biological Processes
Transcriptomic analysis of T-cells derived from pediatric patients with obesity and B-ALL revealed that T-cells express significantly lower levels of genes encoding T-cell receptor components, coreceptors (CD4 and CD8), T-cell receptor associated tyrosine kinases (FYN), and cytolytic genes (PRF1) compared to results obtained from healthy donors and lean pediatric donors with B-ALL. These transcriptional signatures translated to dysfunctional pediatric patient-derived T-cells from donors with obesity, where we observed that ex vivo stimulation resulted in defective cytokine production (IFN-γ/TNF-α) and attenuated upregulation of cytolytic proteins (perforin/granzyme B).
Engineering CAR T-cells from pediatric donors with B-ALL revealed that the body mass index (BMI) of the patient did not impact the post-transduction viability of CAR T-cells nor the percentage of CAR-expressing CAR T-cells. However, CAR T-cells generated from patients with obesity expressed higher surface levels of immune checkpoint proteins (Tim-3/Lag-3/Pd-1) and failed to consume glycine and alanine, which are amino acids critical for T-cell proliferation and function. Furthermore, co-culturing patient-derived CAR T-cells with human B-ALL cell lines revealed that CAR T-cells generated from pediatric donors with obesity expressed lower protein levels of granzyme B which correlated with a reduction in the killing efficiency of leukemia cells at all effector to target (E:T) cell ratios tested. These results may explain our previously reported retrospective results, where pediatric and young adult patients with obesity and relapsed/refractory B-ALL experienced significant reductions in progression-free survival and overall survival when treated with commercially manufactured Tisagenlecleucel (Ross et al., 2022 ASH Conference). However, obesity may further complicate the efficacy of CAR T-cell therapy in pediatric patients due to our observation that the obese bone marrow microenvironment reduces CD19 surface expression on human B-ALL cells.
Importantly, we were able to recapitulate these findings using murine models of diet-induced obesity. In these studies, CAR T-cells engineered from obese compared to lean mice displayed the same phenotypes as the patient-derived samples including no changes in CAR T-cell viability, similar CAR expression in engineered products, and defective cytolysis of leukemia cells in co-culture assays with CAR T-cells and murine B-ALL cells, particularly at higher E:T ratios. In syngeneic studies conducted in lean mice transplanted with B-ALL cells, we found treatment with CAR T-cells engineered from lean mice conferred complete protection from B-ALL; whereas, treating lean mice with CAR T-cells made from obese mice resulted in over 60 percent of the mice succumbing to disease within 2 months.
Overall, our clinical and pre-clinical findings demonstrate that obesity impairs CD19-directed CAR T-cell therapy in pediatric B-ALL largely due to cell autonomous defects in T-cells which cannot by overcome by the introduction of CD3/CD28-expressing CARs. Furthermore, the efficacy of CAR T-cell therapy is negatively impacted by adipocyte-mediated downregulation of CD19 on bone marrow-derived human B-ALL cells.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts